In October 2013 we had to cease trialing the process due to lack of available and sustainable funds. The new initiative to generate investment into the company will allow us to recommence these trials and move towards selling the product on the open market. As a result, the Company is still in development and approval stage. In February 2014 we appointed an IR company who are looking to raise the estimated $2million required to obtain FDA approval of the patented process to make the product available to our targeted markets.
News 
Market Data 
Discover 
